Last update: Jan. 15, 2019

Anastrozole

Very High Risk for breastfeeding


Very unsafe. Contraindicated.
Use of an alternative or cessation of breastfeeding.

Anastrozole is a selective aromatase inhibitor (estrogen synthetase), which inhibits the secretion of estrogen.
Indicated in the treatment of breast cancer in postmenopause.
Oral administration once a day for prolonged periods.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (low molecular weight, low protein binding and prolonged half-life) enables transfer to breastmilk in amounts which could be significant.

Pharmacokinetics show that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasma concentrations of the drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again (Anderson 2016).

According to this data, the interruption would be for a period of between 10.4 days (5 T½) to 14.6 days (7 T½) after the administration of the last dose, which coincides with the estimates of various authors: 10 days (Schaefer 2007, p 741) to 15 days (Hale 2017, p 66).

Its long elimination half-life and its administration every 24 hours over many months make it impossible to continue breastfeeding.

Alternatives

We do not have alternatives for Anastrozole.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Anastrozole belongs to this group or family:

Tradenames

Main tradenames from several countries containing Anastrozole in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 293 daltons
Protein Binding 40 %
pKa 2,01 -
Tmax 2 hours
T1/2 40 - 50 hours

References

  1. Hale TW, Rowe HE. Medications & Mothers' Milk. A Manual of Lactation Pharmacology. Springer Publishing Company. 2017
  2. Anderson PO. Cancer Chemotherapy. Breastfeed Med. 2016 May;11:164-5. Abstract Full text (link to original source) Full text (in our servers)
  3. AEMPS-Stada. Anastrozol. Ficha técnica. 2016 Full text (in our servers)
  4. Astra-Zeneca. Anastrozole. Data Sheet. 2010 Full text (in our servers)
  5. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, second edition. London. 2007

Total visits

3,232

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM